Dr. Robert M. Cooper
Claim this profileKaiser Permanente Downey Medical Center
Expert in Cancer
Expert in Neuroblastoma
49 reported clinical trials
95 drugs studied
About Robert M. Cooper
Education:
- Earned an MD from Eastern Virginia Medical School.
Experience:
- Specializes as a Pediatric Hematologist and Oncologist.
- Serves as Principal Investigator for clinical trials at Kaiser Permanente Los Angeles Medical Center.
- Director of the Public Cord Blood Banking Program for Kaiser Permanente Southern California.
- Holds the position of Physician Director of the cancer program at the Los Angeles Medical Center.
- Actively involved as Site Principal Investigator for clinical trials in collaboration with the Children's Oncology Group.
Area of expertise
1Cancer
Global LeaderStage I
Stage IV
Stage II
2Neuroblastoma
Global LeaderStage IV
MYC positive
MYC negative
Affiliated Hospitals
Clinical Trials Robert M. Cooper is currently running
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
DAY101
for Langerhans Cell Histiocytosis
This trial tests the safety and effectiveness of tovorafenib (DAY101) in children and young adults with Langerhans cell histiocytosis that is worsening, has returned, or does not respond to other treatments. Tovorafenib is taken orally and works by blocking enzymes needed for cancer cell growth. The study aims to find the best dose and observe the response and side effects over time.
Recruiting1 award Phase 228 criteria
More about Robert M. Cooper
Clinical Trial Related8 years of experience running clinical trials · Led 49 trials as a Principal Investigator · 16 Active Clinical TrialsTreatments Robert M. Cooper has experience with
- Cyclophosphamide
- Etoposide
- Vincristine Sulfate
- Nivolumab
- Doxorubicin Hydrochloride
- Radiation Therapy
Breakdown of trials Robert M. Cooper has run
Cancer
Neuroblastoma
Lymphoma
Rhabdomyosarcoma
Adult T-Cell Leukemia/Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Robert M. Cooper specialize in?
Is Robert M. Cooper currently recruiting for clinical trials?
Are there any treatments that Robert M. Cooper has studied deeply?
What is the best way to schedule an appointment with Robert M. Cooper?
What is the office address of Robert M. Cooper?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.